Schild Raphael, Dupont Simeon, Harambat Jérôme, Vidal Enrico, Balat Ayşe, Bereczki Csaba, Bieniaś Beata, Brandström Per, Broux Francoise, Consolo Silvia, Gojkovic Ivana, Groothoff Jaap W, Hommel Kristine, Hubmann Holger, Braddon Fiona E M, Pankratenko Tatiana E, Papachristou Fotios, Plumb Lucy A, Podracka Ludmila, Prokurat Sylwester, Bjerre Anna, Cordinhã Carolina, Tainio Juuso, Shkurti Enkelejda, Spartà Giuseppina, Vondrak Karel, Jager Kitty J, Oh Jun, Bonthuis Marjolein
Division of Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Pediatrics, Bordeaux University Hospital, Bordeaux Population Health Research Center UMR 1219, University of Bordeaux, Bordeaux, France.
Clin Kidney J. 2023 Jan 12;16(4):745-755. doi: 10.1093/ckj/sfad008. eCollection 2023 Apr.
Data on comorbidities in children on kidney replacement therapy (KRT) are scarce. Considering their high relevance for prognosis and treatment, this study aims to analyse the prevalence and implications of comorbidities in European children on KRT.
We included data from patients <20 years of age when commencing KRT from 2007 to 2017 from 22 European countries within the European Society of Paediatric Nephrology/European Renal Association Registry. Differences between patients with and without comorbidities in access to kidney transplantation (KT) and patient and graft survival were estimated using Cox regression.
Comorbidities were present in 33% of the 4127 children commencing KRT and the prevalence has steadily increased by 5% annually since 2007. Comorbidities were most frequent in high-income countries (43% versus 24% in low-income countries and 33% in middle-income countries). Patients with comorbidities had a lower access to transplantation {adjusted hazard ratio [aHR] 0.67 [95% confidence interval (CI) 0.61-0.74]} and a higher risk of death [aHR 1.79 (95% CI 1.38-2.32)]. The increased mortality was only seen in dialysis patients [aHR 1.60 (95% CI 1.21-2.13)], and not after KT. For both outcomes, the impact of comorbidities was stronger in low-income countries. Graft survival was not affected by the presence of comorbidities [aHR for 5-year graft failure 1.18 (95% CI 0.84-1.65)].
Comorbidities have become more frequent in children on KRT and reduce their access to transplantation and survival, especially when remaining on dialysis. KT should be considered as an option in all paediatric KRT patients and efforts should be made to identify modifiable barriers to KT for children with comorbidities.
关于接受肾脏替代治疗(KRT)儿童的合并症数据稀缺。鉴于合并症对预后和治疗具有高度相关性,本研究旨在分析欧洲接受KRT儿童合并症的患病率及其影响。
我们纳入了欧洲儿科肾脏病学会/欧洲肾脏协会登记处中2007年至2017年开始接受KRT时年龄小于20岁的患者数据,这些患者来自22个欧洲国家。使用Cox回归估计有合并症和无合并症患者在肾移植(KT)可及性以及患者和移植物存活方面的差异。
在开始接受KRT的4127名儿童中,33%存在合并症,自2007年以来患病率以每年5%的速度稳步上升。合并症在高收入国家最为常见(43%,而低收入国家为24%,中等收入国家为33%)。有合并症的患者接受移植的机会较低{调整后风险比[aHR]为0.67[95%置信区间(CI)0.61 - 0.74]},死亡风险较高[aHR为1.79(95%CI 1.38 - 2.32)]。死亡率增加仅见于透析患者[aHR为1.60(95%CI 1.21 - 2.13)],而在接受KT后未出现。对于这两个结局,合并症在低收入国家的影响更强。合并症的存在不影响移植物存活[5年移植物失败的aHR为1.18(95%CI 0.84 - 1.65)]。
接受KRT的儿童中合并症变得更为常见,并且会降低他们接受移植的机会和存活率,尤其是在继续接受透析时。应将KT视为所有儿科KRT患者的一种选择,并应努力确定合并症儿童接受KT的可改变障碍。